GlobeNewswire·Mar 6, 2026, 8:00 AM ET

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Allarity Therapeutics closed a $20 million non-convertible debt financing with Streeterville Capital on March 6, 2026.
The transaction consists of two promissory notes: one for $10,930,000 and a secured note for $10,000,000.
Proceeds extend the company's cash runway into the summer of 2028.
Funds will primarily support Phase 2 trial completion, FDA meeting preparation, companion diagnostic strategy, and advancement toward pivotal development for stenoparib in ovarian cancer.
Stenoparib (2X-121) is a dual PARP and WNT pathway inhibitor showing durable clinical benefits in heavily pre-treated ovarian cancer patients, with some remaining on therapy over 30 months.
Two Phase 2 protocols are active, including an amended protocol for platinum-resistant or platinum-ineligible patients designed to accelerate development toward FDA approval.
The company utilizes its Drug Response Predictor (DRP) companion diagnostic platform to select patients with a high likelihood of benefiting from stenoparib based on gene expression signatures.
Allarity holds exclusive global rights to stenoparib, originally developed by Eisai Co. Ltd.
A Form 8-K detailing the transaction was filed with the SEC on March 6, 2026.